SCHEMBL7146795

SCHEMBL7146795

Cc1ccc(COc2ccc(OCc3ccc(C)cc3)c(C=O)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 11/20 0.58
MAOA P21397 5/20 0.58
TUBB1 Q9H4B7 1/20 0.58
ALDH1A1 P00352 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
HPGD P15428 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RECQL P46063 1/20 0.49
ACHE P22303 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PARP10 Q53GL7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149558 0.88 MAOB (0.58) MAOBMAOATUBB1ALDH1A1LMNA
SCHEMBL7147744 0.88 TUBB1 (0.66) MAOBTUBB1ALDH1A1LMNAMAPT
SCHEMBL5286017 0.85 ALDH1A1 (0.56) MAOBMAOATUBB1ALDH1A1LMNA
SCHEMBL7150750 0.85 TUBB1 (0.55) MAOBMAOATUBB1MAPTL3MBTL1
SCHEMBL3615463 0.84 MAOB (0.58) MAOBMAOATUBB1MAPTSMN1; SMN2
SCHEMBL5699833 0.84 LMNA (0.69) MAOBMAOAALDH1A1LMNAMAPT
SCHEMBL21347524 0.83 TUBB1 (0.59) TUBB1ALDH1A1LMNAMAPTHPGD
SCHEMBL14367331 0.82 ALDH1A1 (0.60) MAOBMAOATUBB1ALDH1A1LMNA
SCHEMBL28611584 0.82 TUBB1 (0.74) MAOBTUBB1ALDH1A1LMNAMAPT
SCHEMBL13581057 0.81 TUBB1 (0.51) MAOBMAOATUBB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA MAOB 3505/4885MAOA 3492/4885TUBB1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.